The price increase follows a positive statement from British drug authorities regarding the use of higher doses of Wegovy for people with obesity. Also helping is that analysts at brokerage house Berenberg and at Bank of America have raised their target prices on Novo Nordisk shares, while analysts at Deutsche Bank describe the stock as one of their favorites.
American arch-rival Eli Lilly is down just over 1 percent in futures trading on Wall Street.
Novo Nordisk had a weak stock-market performance last year, but has recovered somewhat so far this year with a total increase of 18 percent.
